Dyslipidemia | Unmet Need | US/EU | 2021
Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including PCSK9 inhibitors and Vascepa, the ability to reduce the risk of CV morbidity and mortality is highly desired by physicians. We discuss how current therapies are differentiated based on the performance of key drug attributes and measure the impact of these attributes on physicians’ prescribing behavior. We also assess the most important unmet needs in the treatment of dyslipidemia and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for dyslipidemia.
QUESTIONS ANSWERED
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- Which dyslipidemia therapies are perceived by U.S. and European physicians as performing best on key treatment drivers and goals?
- What are the major areas of opportunity for drug developers in dyslipidemia treatment and their likelihood of being fulfilled in the near future?
- Based on the conjoint analysis and target product profile (TPP) simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new dyslipidemia drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in March 2021
Key companies: Amgen, Regeneron, Amarin, Esperion, Novartis, Merck
Key drugs: Repatha, Vascepa, Nexletol / Nilemdo, Nexlizet / Nustendi, ezetimibe, fibrates, omega-3 acid ethyl esters
